Tagged with Pricing

Opinion Despite the savings and increased patient access biosimilars have brought to health care systems across Europe, the US has been surprisingly slow in their adoption. Chip Davis, President and CEO, Association for Accessible Medicines breaks down the systematic challenges that must be addressed in order for the US biosimilars market to realize…

France The healthcare and life sciences industries, as they become more advanced and complex, increasingly require government involvement to ensure clinical compliance, ethical behaviour and the well-being of the nation. The health sector is subject to mounting regulatory pressures meaning politics must play a key role. As we advance more and more in healthcare…

China Aditya Bhattacharji manages Eurasia Group‘s healthcare analysis. Together with his colleague Sarah Hassan, a researcher at the company they look at China’s skyrocketing health industry and what to expect from it in the Year of the Pig, 2019.    China approved a record 48 new drugs last year, despite a significant organizational restructuring.…

India Anay Shukla leads the pharmaceutical, life sciences, med-tech and healthcare practice at Nishith Desai Associates, a leading Indian law firm. In this article, he examines the benefit of the recent policy changes to price controls for innovative drugs in India.  Unlike many other countries, India controls prices of all drugs…

IFPMA Across the month of January, we at PharmaBoardroom surveyed our executive readership on attitudes towards the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)’s new Code of Practice, effective January 1st, 2019. To download the Code click here and to read our exclusive interview with Melissa Barnes, the IFPMA’s ethics…

UK In recent years, apocalyptic conversations around superbugs caused by antimicrobial resistance (AMR) have been on the up, but just in case we were becoming immune to these warnings, the UK has dropped a big announcement that not only indicates the country’s commitment to the problem but also the imminent threat that…

China In late 2018 China adopted a novel procurement scheme with the aim of dramatically cutting the amount being paid for generic drugs. The policy’s effect on pricing stands to hit domestic generic firms hardest unless they adapt their business models. Big Pharma could also lose out as their off-patent originators…

Opinion Aditya Bhattacharji manages Eurasia Group‘s healthcare analysis. In this article, he gives his predictions for the political landscape in healthcare for 2019.  The challenges for firms are painfully apparent—there is bipartisan support in the US to lower drug prices, a pervasive sense that traditional advocacy methods are failing in today’s political climate,…

France Maurice-Pierre Planel, president of the CEPS (Comité économique des produits de santé), details how the French government is unique in the way that they engage in drug pricing and comments on how the transformation of the French healthcare system will impact the CEPS’s role in price negotiation.   You are…

Regulation Chester “Chip” Davis, Jr, the President and CEO of the Association for Accessible Medicines (AAM) in the United States, discusses the contradictory nature of Trump’s efforts to lower drug prices.    The President has forcefully pledged to provide relief to these patients and their families, but his own trade policy threatens…

Turkey Dr. Hakkı Gürsöz, president of the Turkish Medicines and Medical Devices Agency (TiTCK), provides insights into recent localization and pricing policies and delivers strong messages to both domestic and foreign companies operating in Turkey while underlining TiTCK’s ambitions to work hand-in-hand with the industry, the world’s most respected regulatory authorities…

Valeant Valeant Pharmaceuticals has taken the decision to rename itself in an effort to distance the company from a series of pricing scandals that occurred under previous CEO J. Michael Pearson. Following the loss of nearly 93 percent of its value, the much maligned firm has announced that it will adopt…